Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins

Abstract

PURPOSE Although preclinical, epidemiological and prior clinical trial data suggest that green tea catechins (GTCs) may reduce prostate cancer (PCa) risk, several preclinical studies and case reports have reported liver toxicities and acute gastrointestinal bleeding. Based on these observations, regulatory bodies have required stringent inclusion criteria… (More)
DOI: 10.18632/oncotarget.12222

4 Figures and Tables

Topics

  • Presentations referencing similar topics